Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 23, 2019

Primary Completion Date

February 25, 2020

Study Completion Date

October 31, 2020

Conditions
Retinitis PigmentosaRetinal DiseasesRetinal Degeneration
Interventions
BIOLOGICAL

Gene Therapy product:vMCO-I

The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Trial Locations (1)

753014

JPM Rotary Club of Cuttack Eye Hospital and Research Institute, Cuttack

Sponsors
All Listed Sponsors
lead

Nanoscope Therapeutics Inc.

INDUSTRY

NCT04919473 - Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter